Oxular – Developing novel drug/device combination treatments for sight threatening retinal diseases.

Targeted, safe, long-lasting retinal treatments

Oxular is transforming the treatment of retinal disorders to improve patients’ vision so they can live better lives.

Targeted, safe, long-lasting retinal treatments

Oxular is transforming the treatment of retinal disorders to improve patients’ vision so they can live better lives.

Latest News

Oxular at the Dry AMD Therapeutic Development Conference

Oxular Limited Appoints James Jogerst as CBO

Oxular & ISU 2022

Latest News

Oxular's innovative technology...

Targeted, routine suprachoroidal delivery

Long-lasting treatments

...transforms the treatment paradigm…

...to offer novel approaches for retinal specialists and meaningful benefits for patients.

Best-in-class or first-in-class treatments
Sustained treatment benefits, leading to fewer injections and better patient outcomes and adherence
Better safety through targeted drug delivery with enriched choroidal-retinal exposure
Reduced treatment burden and related costs for healthcare systems

Putting innovation into action

Targeted, routine, suprachoroidal delivery		Long-lasting treatments
Oxulumis®		Oxuspheres™



	Pipeline programs
High prevalence retinal disorders		Ocular oncology
Diabetic macular edema (DME), retinal vein occlusion (RVO), uveitis Diabetic retinopathy		Retinoblastoma Radiation maculopathy

	Future opportunities
Indications		Modalities
Geographic atrophy / intermediate AMD Neovascular AMD Uveal melanoma Neuroprotection Front-of-eye		Small molecules AAV gene therapies Peptides/proteins Antibodies siRNA

Building a leading retinal therapeutics franchise

Oxular is committed to transforming the treatment paradigm for sight-threatening retinal disorders by providing safe, durable therapeutics that are precisely delivered to specific ocular tissues to control disease activity.

We have…